Verition Fund Management LLC Sells 1,349 Shares of Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH)

Verition Fund Management LLC lessened its holdings in shares of Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) by 20.7% during the 3rd quarter, Holdings Channel.com reports. The fund owned 5,162 shares of the company’s stock after selling 1,349 shares during the period. Verition Fund Management LLC’s holdings in Amphastar Pharmaceuticals were worth $251,000 as of its most recent SEC filing.

A number of other institutional investors have also recently added to or reduced their stakes in the business. Aurora Investment Counsel raised its holdings in shares of Amphastar Pharmaceuticals by 0.4% during the 3rd quarter. Aurora Investment Counsel now owns 54,698 shares of the company’s stock valued at $2,654,000 after purchasing an additional 232 shares in the last quarter. GAMMA Investing LLC raised its holdings in Amphastar Pharmaceuticals by 70.0% during the third quarter. GAMMA Investing LLC now owns 663 shares of the company’s stock valued at $32,000 after buying an additional 273 shares in the last quarter. Crossmark Global Holdings Inc. lifted its position in shares of Amphastar Pharmaceuticals by 2.5% in the second quarter. Crossmark Global Holdings Inc. now owns 11,300 shares of the company’s stock worth $452,000 after buying an additional 275 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. boosted its stake in shares of Amphastar Pharmaceuticals by 20.6% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,761 shares of the company’s stock worth $85,000 after acquiring an additional 301 shares in the last quarter. Finally, Blue Trust Inc. increased its holdings in shares of Amphastar Pharmaceuticals by 23.9% during the 2nd quarter. Blue Trust Inc. now owns 1,604 shares of the company’s stock valued at $70,000 after acquiring an additional 309 shares during the last quarter. 65.09% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling

In other news, EVP Rong Zhou sold 6,893 shares of Amphastar Pharmaceuticals stock in a transaction that occurred on Tuesday, November 12th. The stock was sold at an average price of $48.88, for a total transaction of $336,929.84. Following the sale, the executive vice president now owns 118,388 shares of the company’s stock, valued at approximately $5,786,805.44. This trade represents a 5.50 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Richard K. Prins sold 10,000 shares of Amphastar Pharmaceuticals stock in a transaction on Monday, December 9th. The stock was sold at an average price of $43.77, for a total transaction of $437,700.00. Following the sale, the director now owns 30,471 shares in the company, valued at $1,333,715.67. This represents a 24.71 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 34,533 shares of company stock valued at $1,676,542. 27.10% of the stock is owned by company insiders.

Amphastar Pharmaceuticals Stock Performance

Shares of NASDAQ AMPH opened at $42.24 on Friday. Amphastar Pharmaceuticals, Inc. has a 12 month low of $36.56 and a 12 month high of $65.92. The company has a market cap of $2.03 billion, a P/E ratio of 14.08, a P/E/G ratio of 0.87 and a beta of 0.78. The business’s 50 day moving average is $47.14 and its two-hundred day moving average is $44.63. The company has a quick ratio of 2.61, a current ratio of 3.43 and a debt-to-equity ratio of 0.82.

Wall Street Analysts Forecast Growth

AMPH has been the subject of several analyst reports. StockNews.com lowered Amphastar Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Friday, November 1st. Wells Fargo & Company started coverage on shares of Amphastar Pharmaceuticals in a report on Friday, November 22nd. They set an “equal weight” rating and a $55.00 price objective for the company. Three investment analysts have rated the stock with a hold rating and two have issued a buy rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus price target of $60.33.

Amphastar Pharmaceuticals Company Profile

Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency.